ChemicalBook > Product Catalog >API >Circulatory system drugs >Angina Pectoris Drugs >Cyclovirobuxin D

Cyclovirobuxin D

Cyclovirobuxin D Structure
CAS No.
860-79-7
Chemical Name:
Cyclovirobuxin D
Synonyms
cvb-d;bebuxine;NSC91722;cyclobuxine D;CYCLOVIROBUXINE;cyclovirobuxind;CYCLOVIROBUXINE D;-bis(methylamino)-;cyclovirobuxinum D;Cyclovirobuxine D, >=98%
CBNumber:
CB3663206
Molecular Formula:
C26H46N2O
Molecular Weight:
402.66
MOL File:
860-79-7.mol
MSDS File:
SDS
Modify Date:
2023/6/8 9:01:59

Cyclovirobuxin D Properties

Melting point 220-221 °C (decomp)(Solv: acetone (67-64-1))
Boiling point 524.75°C (rough estimate)
Density 0.9815 (rough estimate)
refractive index 1.5300 (estimate)
storage temp. Store at -20°C
solubility Soluble to 20 mg/mL (49.66 mM) in Ethanol
form cryst.
pka 15.12±0.70(Predicted)
color White
LogP 4.635 (est)
CAS DataBase Reference 860-79-7(CAS DataBase Reference)

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS06
Signal word  Danger
Hazard statements  H301
Precautionary statements  P264-P270-P301+P310-P321-P330-P405-P501
Safety Statements  24/25
HS Code  29420000
Toxicity LD50 oral in mouse: 293mg/kg
NFPA 704
0
2 0

Cyclovirobuxin D Chemical Properties,Uses,Production

Description

A Buxus alkaloid of the steroidal class, this base has been found in the strong base fraction of the alkaloidal extract from Buxus microphylla Sieb. et Zucco var. suffruticosa and B. microphylla Sieb. et Zucco var. suffruticosa Makino forma major. It is dextrorotatory having a specific rotation of [α]23D + 98° (c 4.40,CHC13)and yields a series of salts and derivatives including the dihydrobromide, m.p. 288-292°C (dec.); dihydriodide, m.p. 276-8°C (dec.); diperchlorate, m.p. 244- 5°C (dec.); dioxalate as an amorphous powder, m.p. 264-7°C (dec.): the N:Ndiacetyl derivative, m.p. 278-281°C (dec.) with [α]24D + 10° (c 1.94, CHC13) and the O,N,N-triacetyl derivative, m.p. 246-8°C with [α]24D - 12° (c 2.40, CHCI3)·
The structure and stereochemistry of the base have been elucidated from chemical analysis, spectroscopic evidence and comparison with other alkaloids of this class.

Physical properties

Appearance: colorless needle crystals. Solubility: sparingly soluble in acetone; slightly soluble in water; freely soluble in chloroform; soluble in methanol and ethanol. Melting point: 219–222?°C.

History

Cyclovirobuxine in the treatment of coronary heart disease began in 1969 . The medical teams of Chinese People’s Liberation Army No.86489 explored a treatment of coronary heart disease named Guo, prescription composed of Buxus microphylla (huangyangmu), Salvia miltiorrhiza Bge. (danshen), Ligustici Chuanxiong Rhizoma (chuanxiong), Belamcandae Rhizoma (shegan), Radix Aristolochiae (qingmuxiang) and Asari Radix et Rhizoma (xixin).
In 1978, the Anhui Huangyang Research Cooperation Group carried out systematic experiments to determine the chemical structure and the separation and identification method of cyclovirobuxine by melting point determination, thin-layer chromatography, infrared spectroscopy, mass spectrometry and NMR . Three studies containing more than 300 cases of coronary heart disease patients treated with cyclovirobuxine showed that this drug can significantly improve angina, chest tightness, arrhythmia and other symptoms caused by coronary heart disease.

Uses

Cyclovirobuxine D is a potential preventative agent of cardiac dysfunction.

Indications

It is mainly used for the treatment of cardiovascular and cerebrovascular diseases in China, such as the coronary heart disease, arrhythmia, cerebral arteriosclerosis, cerebral embolism and brain vascular accident which are caused by insufficiency of cerebral blood supply.

Pharmacology

Pharmacological studies have shown that cyclovirobuxine has a positive inotropic effect on the heart that may predominantly be due to the inhibition of cardiomyocyte membrane Na+-K+-ATPase activity and promotion of myocardial extracellular Ca2+ influx and cardiomyocyte Ca2+ release. Moreover, cyclovirobuxine could markedly reduce myocardial oxygen consumption and increase coronary blood flow, suggesting that it has definite anti-myocardial ischemia effect. Experiments also showed that cyclovirobuxine could induce marked inhibition of myocardial ischemia infarction and enhancement of anoxia tolerance in mice .
Besides, cyclovirobuxine could have protective effect on the acute experimental cerebral ischemia in mice by bilateral ligation of common carotid arteries, prolong the life span of mice, increase blood flow and decrease the formation of thrombus during cerebral ischemia . In vitro experiments have also shown that cyclovirobuxine has neuroprotective effects on neurons and restrains PC12 cells from excitatory amino acid-induced injury .

Clinical Use

After decades of clinical observation, cyclovirobuxine has the therapeutic role of anti-myocardial ischemia and antiarrhythmia and protects against acute cerebral ischemia. In addition, cyclovirobuxine can cross the blood-brain barrier and improve brain microcirculation and oxygen supply to treat cerebral arteriosclerosis insufficiency.

References

Nakano, Terao, Tetrahedron Lett., 1035, 1045, (1964)
Brown, Kupchan, J. Amer. Chem. Soc., 86, 4414, 4424 (1964)
Nakano, Terao,J. Chem. Soc., 4512, 4537 (1965)
Nakano, Hasegawa, ibid, 6688 (1965)

Cyclovirobuxin D Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 207)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29900 58 Inquiry
Chengdu Biopurify Phytochemicals Ltd. +8618080483897 China 3424 58 Inquiry
Shaanxi Pioneer Biotech Co., Ltd . +8613259417953 China 3000 58 Inquiry
BOC Sciences +1-631-485-4226 United States 19553 58 Inquiry
Chongqing Chemdad Co., Ltd +86-023-6139-8061 +86-86-13650506873 China 39916 58 Inquiry
CONIER CHEM AND PHARMA LIMITED +8618523575427 China 49391 58 Inquiry
Neostar United (Changzhou) Industrial Co., Ltd. +86-519-519-85557386 China 12210 58 Inquiry
SIMAGCHEM CORP +86-13806087780 China 17367 58 Inquiry
Hubei Ipure Biology Co., Ltd +8613367258412 China 10326 58 Inquiry
Hefei TNJ Chemical Industry Co.,Ltd. 0551-65418671 China 34571 58 Inquiry
CYCLOVIROBUXINE CYCLOVIROBUXINE D 9,19-CYCLOPREGNANE-3,20-DIAMINE,N,N',4,4,14-PENTAMETHYL-, (3,5,20S)- Cyclovirobuxin D(Bebuxine,Cyclovirobuxine D, NSC 91722 ) Cyclovirobuxin D(Bebuxine) 9,19-Cyclopregnan-16-ol, 4,4,14-trimethyl-3,20-bis(methylamino)-, (3β,5α,16α,20S)- Cyclovirobuxine D, >=98% NSC91722 9,19-cyclo-5-alpha,9-beta-pregnan-16-alpha-ol,4,4,14-trimethyl-3-beta,20-alpha bebuxine -bis(methylamino)- cvb-d cyclovirobuxind cyclovirobuxinum D cyclobuxine D 9,19-Cyclopregnan-16-ol,4,4,14-trimethyl-3, 20- bis(methylamino)-,(3β,5α,16α,20S)- (3b,5a,16a,20S)-4,4,14-Trimethyl-3,20-bis(methylamino)-9,19-cyclopregnan-16-ol Cyclovirobuxine D, 98%, from Buxus sinica (Rehd. et Wils.) Cheng Cyclovirobuxine D (CVB-D) Cyclovirobuxin D USP/EP/BP Cyclovirobuxin D (CVB-D) 860-79-7 860-79-1 C26H46N2 C26H46N2O chemical reagent pharmaceutical intermediate phytochemical reference standards from Chinese medicinal herbs (TCM). standardized herbal extract Inhibitors Alkaloids